# RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)

> **NCT04567550** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 139 (actual)

## Conditions studied

- Diabetic Retinopathy (DR)
- Center-Involved Diabetic Macular Edema (CI-DME)

## Interventions

- **GENETIC:** ABBV-RGX-314 Dose 1
- **GENETIC:** ABBV-RGX-314 Dose 2
- **GENETIC:** ABBV-RGX-314 Dose 3
- **DRUG:** Topical Steroid
- **GENETIC:** ABBV-RGX-314 Dose 4
- **BIOLOGICAL:** Aflibercept

## Key facts

- **NCT ID:** NCT04567550
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-11-20
- **Primary completion:** 2026-06
- **Final completion:** 2026-12
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2025-09-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04567550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04567550, "RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04567550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*